Base de dados : LILACS
Pesquisa : D12.644.276.374.750.061 [Categoria DeCS]
Referências encontradas : 5 [refinar]
Mostrando: 1 .. 5   no formato [Detalhado]

página 1 de 1

  1 / 5 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-900871
Autor: Echeverri, Alex; Posso-Osorio, Iván; Figueroa, Christian; Suso, Juan-Pablo; Hormaza, Andrés; Bonilla-Abadía, Fabio; Agualimpia, Andrés; Cañas, Carlos A; Tóbón, Gabriel J.
Título: Efectos del belimumab en pacientes colombianos con lupus eritematoso sistémico, un estudio prospectivo observacional / Effects of belimumab in Colombian patients with systemic lupus erythematosus; a prospective observational study
Fonte: Rev. colomb. reumatol;24(3):159-163, jul.-set. 2017. tab.
Idioma: es.
Resumo: Resumen Introducción: El belimumab es un anticuerpo monoclonal tipo IgG1 que se une e inhibe la forma soluble de Blys (estimulador de linfocitos B) y ha mostrado efectividad en el manejo del lupus eritematoso sistémico (LES). Sin embargo, se desconoce su efectividad en una población tan variable étnicamente como la colombiana. Métodos: Se realizó un estudio prospectivo observacional entre febrero de 2015 y febrero de 2016, en pacientes con LES, con enfermedad activa a pesar del tratamiento estándar, quienes fueron tratados con belimumab. Resultados: El uso de belimumab se relacionó con una mejoría significativa en los compromisos articular, cutáneo y hematológico, con aumento de los niveles de complemento, disminución de las exacerbaciones por LES y de las hospitalizaciones, además de una menor actividad calculada por SLEDAI después de 3 meses de utilización y con una estabilidad mantenida hasta los 9 meses. Conclusiones: Se observó que el belimumab es útil en pacientes colombianos con LES que son refractarios a la terapia estándar, especialmente en manifestaciones articulares, hematológicas y cutáneas, en un entorno de pacientes de la vida real.

Abstract Introduction: Belimumab, a monoclonal type Ig G1 antibody that binds and inhibits the Belimumab soluble form of the Blys (B lymphocyte stimulator) has shown to be effective in the manamanagement of systemic lupus erythematosus (SLE). However, its effectiveness is unknown in an ethnically variable population, such as in Colombia. Methods: A prospective observational study was conducted between February 2015 and February 2016 on patients with active SLE disease despite being on standard treatment and who were treated with Belimumab. Results: Belimumab showed a significant improvement in joint, cutaneous and haematological involvement, with an increase in complement levels, a decrease in lupus crises and hospital admissions. After 3 months there was lower activity, calculated by SLEDAI, with stability for 9 months. Conclusions: In a real-life patient setting, it was observed that belimumab was useful in Colombian patients with SLE and refractory to standard therapy, especially in the joint, haematological, and cutaneous manifestations.
Descritores: Imunoglobulina G
Lúpus Eritematoso Sistêmico
-Terapêutica
Colômbia
Fator Ativador de Células B
Limites: Humanos
Responsável: CO356.9


  2 / 5 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-960209
Autor: Ospina, Fabio Enrique; Betancur, Juan Felipe; Suso, Juan Pablo; Muñoz-Buitro, Evelyn; Cañas, Carlos Alberto; Tobón, Gabriel J.
Título: Papel de la citocina BAFF en las enfermedades autoinmunes: rol fisiopatológico y estrategias terapéuticas / Role of the cytokine BAFF in autoimmune diseases: physiopathology and therapeutic targets
Fonte: Rev. colomb. reumatol;23(3):177-194, jul.-set. 2016. ilus, tab.
Idioma: es.
Resumo: El complejo BAFF (factor activador de células B) compuesto por la citocina BAFF, APRIL y sus receptores -BAFF-R (BR3), TACI y BCMA- influyen en la sobrevida periférica, en la maduración de los linfocitos B y en el cambio de clase de las inmunoglobulinas, con múltiples implicaciones clínicas potenciales. Las funciones biológicas de BAFF y su relevancia en varios desórdenes clínicos -autoinmunes, neoplásicos, infecciosos, incluyendo las terapias BAFF dirigidas- son revisadas y discutidas en el presente artículo. Los niveles séricos de BAFF/APRIL se encuentran incrementados en las enfermedades autoinmunes en las que sus concentraciones se relacionan con los títulos de anticuerpos, actividad, progresión de la enfermedad e incluso compromiso orgánico, haciendo de su inhibición un blanco terapéutico atractivo

The BAFF complex (B cell activator factor) composed by the BAFF cytokine, APRIL and their receptors -BAFF-R (BR3), TACI, BCMA- influences B-lymphocyte maturation, peripheral survival and immunoglobulins class isotype switching, with multiple potential clinical implications. In this review we discuss BAFF biologic functions and it relevance in several clinical disorders -autoimmune, neoplastic, infectious and BAFF therapies-. BAFF/APRIL
Descritores: Doenças Autoimunes
Fator Ativador de Células B
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CO356.9


  3 / 5 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-771933
Autor: Duan, J H; Jiang, Y; Mu, H; Tang, Z Q.
Título: Expression of BAFF and BR3 in patients with systemic lupus erythematosus
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;49(3):e4853, Mar. 2016. tab, graf.
Idioma: en.
Projeto: National Clinical Key Foundation of China.
Resumo: The objective of this study was to examine the relationship between the expression of B cell activating factor (BAFF) and BAFF receptor in patients with disease activity of systemic lupus erythematosus (SLE). Real-time RT-PCR was used to examine BAFF mRNA expression in peripheral blood monocytes of active and stable SLE patients and healthy controls. The percentage of BAFF receptor 3 (BR3) on B lymphocytes was measured by flow cytometry. Soluble BAFF levels in serum were assayed by ELISA. Microalbumin levels were assayed by an automatic immune analysis machine. BAFF mRNA and soluble BAFF levels were highest in the active SLE group, followed by the stable SLE group, and controls (P<0.01). The percentage of BR3 on B lymphocytes was downregulated in the active SLE group compared with the stable SLE group and controls (P<0.01). BAFF mRNA levels and soluble BAFF levels were higher in patients who were positive for proteinuria than in those who were negative (P<0.01). The percentage of BR3 on B lymphocytes was lower in patients who were positive for proteinuria than in those who were negative (P<0.01). The BAFF/BR3 axis may be over-activated in SLE patients. BAFF and BR3 levels may be useful parameters for evaluating treatment.
Descritores: Fator Ativador de Células B/metabolismo
Receptor do Fator Ativador de Células B/metabolismo
Lúpus Eritematoso Sistêmico/metabolismo
-Albuminúria/urina
Fator Ativador de Células B/análise
Fator Ativador de Células B/genética
Receptor do Fator Ativador de Células B/análise
Receptor do Fator Ativador de Células B/genética
Linfócitos B/metabolismo
Biomarcadores/metabolismo
Leucócitos Mononucleares/metabolismo
Lúpus Eritematoso Sistêmico/imunologia
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  4 / 5 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-675673
Autor: Brazilian Journal of Medical and Biological Research; Zhang, Bo; Hu, Mintao; Zhang, Peng; Cao, Hong; Wang, Yongzhen; Wang, Zheng; Su, Tingting.
Título: BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;46(5):433-439, maio 2013. graf.
Idioma: en.
Resumo: Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology. A number of questions regarding its etiology are unclear. CD4+CD25+ regulatory T cells (Tregs) play a critical role in self-tolerance and, for unknown reasons, their relative number is reduced in PBC patients. B-cell-activating factor (BAFF) is a key survival factor during B-cell maturation and its concentration is increased in peripheral blood of PBC patients. It has been reported that activated B cells inhibit Treg cell proliferation and there are no BAFF receptors on Tregs. Therefore, we speculated that excessive BAFF may result in Treg reduction via B cells. To prove our hypothesis, we isolated Tregs and B cells from PBC and healthy donors. BAFF and IgM concentrations were then analyzed by ELISA and CD40, CD80, CD86, IL-10, and TGF-β expression in B cells and Tregs were measured by flow cytometry. BAFF up-regulated CD40, CD80, CD86, and IgM expression in B cells. However, BAFF had no direct effect on Treg cell apoptosis and cytokine secretion. Nonetheless, we observed that BAFF-activated B cells could induce Treg cell apoptosis and reduce IL-10 and TGF-β expression. We also showed that BAFF-activated CD4+ T cells had no effect on Treg apoptosis. Furthermore, we verified that bezafibrate, a hypolipidemic drug, can inhibit BAFF-induced Treg cell apoptosis. In conclusion, BAFF promotes Treg cell apoptosis and inhibits cytokine production by activating B cells in PBC patients. The results of this study suggest that inhibition of BAFF activation is a strategy for PBC treatment.
Descritores: Apoptose/efeitos dos fármacos
Linfócitos B Reguladores/efeitos dos fármacos
Linfócitos B/efeitos dos fármacos
Bezafibrato/farmacologia
Citocinas/biossíntese
Cirrose Hepática Biliar/imunologia
-Fator Ativador de Células B
Linfócitos B Reguladores/metabolismo
Ensaio de Imunoadsorção Enzimática
Citometria de Fluxo
Ativação Linfocitária
Limites: Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  5 / 5 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-438422
Autor: Reyes S., Lilian I; León B., Francisca; Rozas V., M. Fernanda; González J., Patricia.
Título: BAFF: Una citoquina reguladora de linfocitos B implicada en autoinmunidad y cáncer linfoide / BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer
Fonte: Rev. méd. Chile;134(9):1175-1184, sept. 2006. ilus, tab.
Idioma: es; en.
Resumo: BAFF (B cell activating factor belonging to the TNF family) is a cytokine implicated in the survival and maturation of peripheral B lymphocytes and T and B cell activation. BAFF binds to three different receptors: TACI, BCMA and BAFF-R, whose expression is restricted to B and T lymphocytes. BAFF and BAFF-R-deficient mice show a dramatic loss of peripheral B lymphocytes and a severely reduced immune response. In contrast, an enhanced BAFF expression leads to B cell hyperplasia and autoimmunity in mice. In vivo, administration of soluble decoy receptors for BAFF effectively decreases disease progression in various autoimmune mouse models. These evidences render BAFF as a potentially new therapeutic target. Elevated BAFF levels have been detected in the serum of patients with autoimmune diseases, such as Systemic Lupus Erythematosus, rheumatoid arthitis, Sjõgren's syndrome, lymphoid cancers and HIV infection. In addition to BAFF receptors, malignant B cells abnormally express BAFF, which attenuates apoptosis through both autocrine and paracrine pathways. The data suggest that an increase in the expression of BAFF induces an enhanced B and T cell activation and the survival of pathologically active B cells. In this article, we review and discuss the participation of BAFF and its receptors in the immune response and its involvement in immunodeficiency, autoimmunity, infections and lymphoid cancers as well as the currently investigated therapies using BAFF antagonists in the treatment of these diseases.
Descritores: Doenças Autoimunes/imunologia
Autoimunidade/fisiologia
Fator Ativador de Células B/imunologia
Linfócitos B/imunologia
Citocinas/imunologia
Linfoma/imunologia
-Doenças Autoimunes/metabolismo
Fator Ativador de Células B/metabolismo
Linfócitos B/metabolismo
Citocinas/metabolismo
Modelos Animais de Doenças
Linfoma/metabolismo
Receptores do Fator de Necrose Tumoral/imunologia
Receptores do Fator de Necrose Tumoral/metabolismo
Limites: Animais
Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde